C1GALT1 Seems to Promote In Vitro Disease Progression in Ovarian Cancer

Chou, Chih-Hsing; Huang, Miao-Juei; Liao, Ying-Yu; Chen, Chi-Hau; Huang, Min-Chuan

doi:10.1097/igc.0000000000000965

Cited by 19 publications

(14 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We demonstrated that OVCAR3 SC exhibit decreased cell proliferation and increased apoptosis compared to parental OVCAR3 cells. These findings are in agreement with the results by Chou et al [ 36 ], who found that the knockdown of the C1GalT1 enzyme leads to decreased growth of OVCA cells [ 36 ]. Moreover, we found that OVCAR3 SC, despite increased cell migration, also exhibit a reduction in the mesothelial clearance capacity and form smaller and less invasive tumours in the mice model.…”

Section: Discussionsupporting

confidence: 93%

Mucins and Truncated O-Glycans Unveil Phenotypic Discrepancies between Serous Ovarian Cancer Cell Lines and Primary Tumours

Coelho

Marcos-Silva

Mendes

et al. 2018

IJMS

View full text Add to dashboard Cite

Optimal research results rely on the selection of cellular models capable of recapitulating the characteristics of primary tumours from which they originate. The expression of mucins (MUC16 and MUC1) and truncated O-glycans (Tn, STn and T) represents a characteristic footprint of serous ovarian carcinomas (SOCs). Therefore, selecting ovarian cancer (OVCA) cell lines that reflect this phenotype is crucial to explore the putative biological role of these biomarkers in the SOC setting. Here, we investigated a panel of OVCA cell lines commonly used as SOC models, and tested whether, when cultured in 2D and 3D conditions, these recapitulate the mucin and O-glycan expression profiles of SOCs. We further explored the role of truncating the O-glycosylation capacity in OVCAR3 cells through knockout of the COSMC chaperone, using in vitro and in vivo assays. We found that the majority of OVCA cell lines of serous origin do not share the mucin and truncated O-glycan footprint of SOCs, although 3D cultures showed a higher resemblance. We also found that genetic truncation of the O-glycosylation capacity of OVCAR3 cells did not enhance oncogenic features either in vitro or in vivo. This study underscores the importance of well-characterized cellular models to study specific features of ovarian cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

Mucins and Truncated O-Glycans Unveil Phenotypic Discrepancies between Serous Ovarian Cancer Cell Lines and Primary Tumours

Coelho

Marcos-Silva

Mendes

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…Chou et al explored the role of C1GALT1 in ovarian cancer [53]. The elevated expression of C1GALT1 was associated with poor survival in ovarian cancer patients.…”

Section: Core-1 Synthase Behaves Differently In Different Cancersmentioning

confidence: 99%

A Systematic Review on the Implications of O-linked Glycan Branching and Truncating Enzymes on Cancer Progression and Metastasis

Gupta

Leon

Rauth

et al. 2020

Cells

View full text Add to dashboard Cite

Glycosylation is the most commonly occurring post-translational modifications, and is believed to modify over 50% of all proteins. The process of glycan modification is directed by different glycosyltransferases, depending on the cell in which it is expressed. These small carbohydrate molecules consist of multiple glycan families that facilitate cell–cell interactions, protein interactions, and downstream signaling. An alteration of several types of O-glycan core structures have been implicated in multiple cancers, largely due to differential glycosyltransferase expression or activity. Consequently, aberrant O-linked glycosylation has been extensively demonstrated to affect biological function and protein integrity that directly result in cancer growth and progression of several diseases. Herein, we provide a comprehensive review of several initiating enzymes involved in the synthesis of O-linked glycosylation that significantly contribute to a number of different cancers.

show abstract

“…There are still some limitations in this study. Besides HNSCC, C1GALT1 is also overexpressed and plays an important role in hepatocellular carcinoma, breast cancers, ovarian cancers, colorectal cancers, prostate cancers, and esophageal cancers 25–30 . It is possible that patients with cancers other than HNSCC may have elevated anti‐C1GALT1 autoantibodies.…”

Section: Discussionmentioning

confidence: 99%

Anti‐C1GALT1 Autoantibody Is a Novel Prognostic Biomarker for Patients With Head and Neck Cancer

2020

View full text Add to dashboard Cite

Objectives The objective of this study is to determine the value of the anti‐ glycoprotein‐N‐acetylgalactosamine 3‐beta‐galactosyltransferase 1 (C1GALT1) autoantibody as a biomarker for distant metastasis and good response to immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma (HNSCC). Methods In this retrospective study with a median follow‐up of 55.7 months, 186 HNSCC patients were enrolled between July 2013 and August 2014. Data were analyzed between April 2018 and November 2019. Titers of autoantibody against the C1GALT1 peptide were measured by ELISA. Student t test, Kaplan–Meier analysis, and univariate and multivariate Cox proportional hazard models were used to evaluate the association of anti‐C1GALT1 autoantibody titer with clinicopathologic factors, survival, and response to immunotherapy. Results Our results showed that high levels of the anti‐C1GALT1 autoantibody is an independent marker for distant metastasis and poor disease‐specific survivals in HNSCC patients. In 19 recurrent or metastatic (R/M) HNSCC patients who have received nivolumab or pembrolizumab, higher autoantibody titers are associated with a better treatment response. Conclusion We propose that the anti‐C1GALT1 autoantibody can serve as a novel biomarker for distant metastasis in HNSCC patients. It is also useful in individualized medicine for R/M HNSCC patients who are considering immunotherapy. Level of Evidence IV Laryngoscope, 131:E196–E202, 2021

show abstract

C1GALT1 Seems to Promote In Vitro Disease Progression in Ovarian Cancer

Abstract: C1GALT1 modifies O-glycan expression and enhances malignant behaviors in ovarian cancer cells, suggesting that C1GALT1 plays a role in the pathogenesis of ovarian cancer and targeting C1GALT1 could be a promising approach for ovarian cancer therapy.

Cited by 19 publications

References 37 publications

Mucins and Truncated O-Glycans Unveil Phenotypic Discrepancies between Serous Ovarian Cancer Cell Lines and Primary Tumours

Mucins and Truncated O-Glycans Unveil Phenotypic Discrepancies between Serous Ovarian Cancer Cell Lines and Primary Tumours

A Systematic Review on the Implications of O-linked Glycan Branching and Truncating Enzymes on Cancer Progression and Metastasis

Anti‐C1GALT1 Autoantibody Is a Novel Prognostic Biomarker for Patients With Head and Neck Cancer

Contact Info

Product

Resources

About